Evaluation of Trastuzumab Deruxtecan with Immunotherapy and Chemotherapy in First-Line Treatment of HER2-Overexpressing Advanced Non-Small Cell Lung Cancer

The primary objective of this study is to evaluate the **safety** and **tolerability** of Trastuzumab Deruxtecan when used in combination with immunotherapy agents, with and without chemotherapy, as a first-line treatment for patients with advanced **HER2 over-expressing Non-Small Cell Lung Cancer** (NSCLC). This is clinically relevant as it aims to determine the potential of this combination therapy to improve treatment outcomes for patients with this specific subtype of lung cancer, which is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2). Understanding the safety profile and tolerability of this regimen is crucial for its potential adoption in clinical practice.

The clinical trial involves a total of **187 participants** diagnosed with **advanced or metastatic non-squamous non-small cell lung cancer (mNSCLC)** characterized by **HER2 overexpression**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, typically encompassing adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not disclosed. The trial includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, or habits were not specified in the available data.

The clinical trial is designed to evaluate the **safety** and tolerability of Trastuzumab Deruxtecan in combination with immunotherapy agents, with and without chemotherapy, as a first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (mNSCLC) characterized by **HER2 overexpression**. This is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date was March 9, 2021, with an anticipated end date of June 30, 2026, indicating a total trial duration of approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the participants' response to treatment and any adverse effects. These visits will be scheduled at regular intervals throughout the study period. The end-of-study visit will occur after the completion of the treatment phase, where final assessments will be conducted to evaluate the primary and secondary endpoints of the trial.

The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Participants may be subject to early termination from the study if they experience significant adverse reactions, fail to comply with study protocols, or withdraw consent. The trial aims to provide comprehensive data on the efficacy and safety of the treatment regimen, contributing valuable insights into the management of HER2 overexpressing mNSCLC.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is in Phase 3 and is expected to conclude by June 30, 2026. The recruitment for the trial began on March 9, 2021. The efficacy of the investigational treatment will be assessed through predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured schedule for measuring and collecting efficacy data, adhering to the standards typical of Phase 3 trials. The analysis of these efficacy parameters will be conducted using scientifically validated methods appropriate for the trial phase. The trial's design and execution will ensure that the efficacy assessments are objective and reliable, contributing to the overall evaluation of the treatment's effectiveness.